The Vanguard Group 13D and 13G filings for TG Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-01-08 11:29 am Purchase | 2024-12-31 | 13G | TG Therapeutics, Inc. TGTX | The Vanguard Group | 15,596,480 10.010% | 1,925,536 (+14.08%) | Filing |
| 2024-02-13 5:15 pm Sale | 2023-12-29 | 13G | TG Therapeutics, Inc. TGTX | The Vanguard Group | 13,670,944 9.030% | -1,831,820 (-11.82%) | Filing |
| 2023-02-09 11:35 am Purchase | 2022-12-30 | 13G | TG Therapeutics, Inc. TGTX | The Vanguard Group | 15,502,764 10.670% | 756,372 (+5.13%) | Filing |
| 2022-10-11 10:07 am Purchase | 2022-09-30 | 13G | TG Therapeutics, Inc. TGTX | The Vanguard Group | 14,746,392 10.150% | 2,654,955 (+21.96%) | Filing |
| 2022-02-10 08:42 am Purchase | 2021-12-31 | 13G | TG Therapeutics, Inc. TGTX | The Vanguard Group | 12,091,437 8.460% | 1,120,574 (+10.21%) | Filing |
| 2021-02-10 11:57 am Purchase | 2020-12-31 | 13G | TG Therapeutics, Inc. TGTX | The Vanguard Group | 10,970,863 8.110% | 10,970,863 (New Position) | Filing |